Search Result

Results for "

CDK9-inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Bcl-2 Family (1) CDK (49) CMV (1) DNA/RNA Synthesis (1) GSK-3 (1) HIV (2) HSV (1) Ligands for Target Protein for PROTAC (2) SARS-CoV (1) Virus Protease (1)
By Research Areas:	Cancer (44) Infection (4) Inflammation/Immunology (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124639

CDK9 inhibitor HH1	CDK	Cancer
CDK9 inhibitor HH1 is a potent and selectively *CDK9* inhibitor. CDK9 inhibitor HH1 inhibits the transcription of CDK. CDK9 inhibitor HH1 can be used in research of cancer .

HY-X0150

JSH-150

CDK Cancer

JSH-150 is a highly selective and potent CDK9 inhibitor with an IC₅₀ of 1 nM.
HY-15878

LDC000067

5+ Cited Publications

LDC067
CDK Apoptosis Cancer

LDC000067 is a highly specific CDK9 inhibitor with an IC₅₀ value of 44±10 nM in vitro.
HY-147026

CDK9-IN-15

CDK Cancer

CDK9-IN-15 (compound 50) is a potent CDK9 inhibitor .
HY-157980

CDK9-IN-32

CDK Cancer

CDK9-IN-32 (compound 006-3) is a CDK9 inhibitor .
HY-102039

CDK9-IN-8

CDK Cancer

CDK9-IN-8 is a highly effective and selective CDK9 inhibitor with an IC₅₀ of 12 nM.
HY-153426

CDK9-IN-23

CDK Cancer

CDK9-IN-23 (Example 4) is a CDK9 inhibitor with an IC₅₀ of <20 nM .
HY-153260

TP-1287

CDK Cancer

TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active CDK9 inhibitor .
HY-147131

CDK9-IN-30

CDK HIV Infection

CDK9-IN-30 is a CDK9 inhibitor that inhibits HIV-1 viral replication .
HY-13033

CDK-IN-2

1 Publications Verification

CDK inhibitor II
CDK Cancer

CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM, extracted from reference 1, example 4.
HY-155844

CDK9-IN-26

CDK Cancer

CDK9-IN-26 (compound 1is a CDK9 inhibitor (IC₅₀=0.18 μM)。 .

JSH-150	CDK	Cancer
JSH-150 is a highly selective and potent *CDK9* inhibitor with an IC₅₀ of 1 nM.

LDC000067 5+ Cited Publications LDC067	CDK Apoptosis	Cancer
LDC000067 is a highly specific *CDK9* inhibitor with an IC₅₀ value of 44±10 nM in vitro.

CDK9-IN-15	CDK	Cancer
CDK9-IN-15 (compound 50) is a potent *CDK9* inhibitor .

CDK9-IN-32	CDK	Cancer
CDK9-IN-32 (compound 006-3) is a *CDK9* inhibitor .

CDK9-IN-8	CDK	Cancer
CDK9-IN-8 is a highly effective and selective *CDK9* inhibitor with an IC₅₀ of 12 nM.

CDK9-IN-23	CDK	Cancer
CDK9-IN-23 (Example 4) is a *CDK9* inhibitor with an IC₅₀ of <20 nM .

TP-1287	CDK	Cancer
TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active *CDK9* inhibitor .

CDK9-IN-30	CDK HIV	Infection
CDK9-IN-30 is a CDK9 inhibitor that inhibits HIV-1 viral replication .

CDK-IN-2 1 Publications Verification CDK inhibitor II	CDK	Cancer
CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM, extracted from reference 1, example 4.

CDK9-IN-26	CDK	Cancer
CDK9-IN-26 (compound 1is a CDK9 inhibitor (IC₅₀=0.18 μM)。 .

HY-13461A

PHA-767491 hydrochloride 3 Publications Verification CAY-10572 hydrochloride	CDK Apoptosis	Cancer
PHA-767491 hydrochloride is a dual *Cdc7/Cdk9* inhibitor, with IC₅₀s of 10 nM and 34 nM, respectively.

HY-112088

AZD4573 5+ Cited Publications	CDK	Cancer
AZD4573 is a potent and highly selective *CDK9* inhibitor (IC₅₀ of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies .

HY-13461

PHA-767491

CAY10572
CDK Cancer

PHA-767491 is a dual Cdc7/Cdk9 inhibitor, with IC₅₀s of 10 nM and 34 nM, respectively.
HY-143584

AZ5576

CDK Cancer

AZ5576 is a potent and highly selective CDK9 inhibitor (IC₅₀: <5 nM). AZ5576 can be used for hematological Malignancy research .

PHA-767491 CAY10572	CDK	Cancer
PHA-767491 is a dual *Cdc7/Cdk9* inhibitor, with IC₅₀s of 10 nM and 34 nM, respectively.

AZ5576	CDK	Cancer
AZ5576 is a potent and highly selective *CDK9* inhibitor (IC₅₀: <5 nM). AZ5576 can be used for hematological Malignancy research .

HY-103019B

(-)-Enitociclib (R)-Enitociclib; (-)-BAY-1251152; (-)-VIP152	CDK	Cancer
(-)-Enitociclib ((R)-Enitociclib) is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective *PTEF/CDK9* inhibitor.

HY-149673

XPW1

CDK Cancer

XPW1 is a potent and selective CDK9 inhibitor with excellent activity against clear cell renal cell carcinoma (ccRCC) and low toxicity .

XPW1	CDK	Cancer
XPW1 is a potent and selective *CDK9* inhibitor with excellent activity against clear cell renal cell carcinoma (ccRCC) and low toxicity .

HY-103019A

(±)-Enitociclib (±)-BAY-1251152; (±)-VIP152	CDK	Cancer
(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective *PTEF/CDK9* inhibitor.

HY-12871C

Atuveciclib S-Enantiomer BAY-1143572 S-Enantiomer	CDK	Cancer
Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective *CDK9* inhibitor, which inhibits *CDK9/CycT1* with an IC₅₀ of 16 nM.

HY-103019

(+)-Enitociclib 2 Publications Verification (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib	CDK	Cancer
(+)-Enitociclib ((+)-BAY-1251152) is an enanthiomer of BAY-1251152 with rotation (+). Enitociclib is a potent and selective *CDK9* inhibitor with an IC₅₀ of 3 nM. Enitociclib has anti-tumour activity .

HY-130852

CDK9-IN-11

CDK Ligands for Target Protein for PROTAC Cancer

CDK9-IN-11 is a potent CDK9 inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628) .
HY-130850

CDK9-IN-10

CDK Ligands for Target Protein for PROTAC Cancer

CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811) .
HY-139980

CDK9-IN-13

CDK Cancer

CDK9-IN-13 (compound 38) is potent and selective CDK9 inhibitor, with an IC₅₀ of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents .
HY-160171

CDK9-IN-31

CDK Cancer

CDK9-IN-31 (Compound Z1) is a CDK9 inhibitor that inhibits cancer cell growth. CDK9-IN-31 has the potential to be developed as an anticancer agent .

CDK9-IN-11	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-11 is a potent *CDK9* inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628) .

CDK9-IN-10	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-10 is a potent *CDK9* inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811) .

CDK9-IN-13	CDK	Cancer
CDK9-IN-13 (compound 38) is potent and selective *CDK9* inhibitor, with an IC₅₀ of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents .

CDK9-IN-31	CDK	Cancer
CDK9-IN-31 (Compound Z1) is a *CDK9* inhibitor that inhibits cancer cell growth. CDK9-IN-31 has the potential to be developed as an anticancer agent .

HY-13231

CDK9-IN-1 2 Publications Verification	CDK HIV	Infection
CDK9-IN-1 is a novel, selective *CDK9* inhibitor for the treatment of HIV infection, with an IC₅₀ of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

HY-12871

Atuveciclib Racemate 1 Publications Verification BAY-1143572 Racemate	CDK	Cancer
Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral *P-TEFb/CDK9** inhibitor* which supresses *CDK9/CycT1* with an IC₅₀ of 13 nM.

HY-12871B

Atuveciclib 5+ Cited Publications BAY-1143572	CDK	Cancer
Atuveciclib (BAY-1143572) is a potent and highly selective, oral *PTEFb/CDK9** inhibitor. Atuveciclib (BAY-1143572) inhibits* *CDK9/CycT1* with an IC₅₀ of 13 nM .

HY-160171A

CDK9-IN-31 dimaleate	CDK	Cancer
CDK9-IN-31 dimaleate (Compound Z1) is a *CDK9* inhibitor that inhibits cancer cell growth. CDK9-IN-31 dimaleate has the potential to be developed as an anticancer agent .

HY-149641

CDK9-IN-29	CDK	Cancer
CDK9-IN-29 (compound Z11) is a potent *CDK9* inhibitor (IC₅₀ = 3.20 nM) with good kinase selectivity. CDK9-IN-29 inhibits cell proliferation and induces apoptosis .

HY-131063

CDK6/9-IN-1	CDK	Cancer
CDK6/9-IN-1 (compound 66) is an orally active active and dual CDK 6 and *CDK 9* inhibitor, with IC₅₀ values of 40.5 nM and 39.5 nM for CDK6 anmd CDK9, respectively .

HY-X0009A

JSH-0009 dimaleate	CDK	Cancer
JSH-0009 dimaleate (Compound 1) is a potent *CDK9* inhibitor with an IC₅₀ of 0.928 nM. JSH-0009 can effectively inhibit the growth of subcutaneous tumor (cute myelogenous leukemia MV4-11) mice .

HY-12871A

(+)-Atuveciclib (+)-BAY-1143572	CDK	Cancer
(+)-Atuveciclib is the isomer of Atuveciclib (Racemate) (HY-12871). Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective，oral *P-TEFb/CDK9** inhibitor* which supresses *CDK9/CycT1* with an IC₅₀ of 13 nM.

HY-130001

CDK9-IN-9	CDK	Cancer
CDK9-IN-9 (example 2) is a potent and selective *CDK9* inhibitor with an IC₅₀ of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC₅₀ of 155 nM. CDK9-IN-9 has anti-cancer activity .

HY-10012

AZD-5438 Maximum Cited Publications 10 Publications Verification	CDK	Cancer
AZD-5438 is a potent CDK1, CDK2, and *CDK9* inhibitor, with IC₅₀s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .

HY-143585

CDK9-IN-14	CDK	Cancer
CDK9-IN-14 is a potent and selective *CDK9* inhibitor with IC₅₀ of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects .

HY-147905

CDK9-IN-18	CDK Apoptosis	Cancer
CDK9-IN-18 is a potent *CDK9* inhibitor. CDK9-IN-18 blocks the phosphorylation function of kinase CDK9. CDK9-IN-18 exhibits both good anticancer activity and low cellular activity. CDK9-IN-18 induces apoptosis.

HY-155153

CDK9-IN-24	Apoptosis CDK	Others
CDK9-IN-24 (compound 21a) is a highly selective *CDK9* inhibitor with significant inhibitory effect on tumor growth. CDK9-IN-24 effectively blocks cell proliferation and induces apoptosis by downregulating Mcl-1 and c-Myc, and can be used in acute myeloid leukemia research .

HY-155843

CDK9-IN-25	CDK SARS-CoV Virus Protease	Infection
CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC₅₀: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC₅₀: 63.28 μM) .

HY-100950

ABC1183	GSK-3 CDK	Inflammation/Immunology Cancer
ABC1183 is an orally active selective dual GSK3 and *CDK9* inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC₅₀ values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities .

HY-16462

CDK9-IN-2 5 Publications Verification	CDK	Cancer
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC₅₀ of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

HY-117203A

CDK12-IN-E9	CDK	Cancer
CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent *CDK9* inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC₅₀> 1 μM .

HY-12445

Asnuciclib 2 Publications Verification CDKI-73; LS-007	CDK Apoptosis	Inflammation/Immunology Cancer
Asnuciclib (CDKI-73; LS-007) is an orally active and highly efficacious *CDK9* inhibitor, with K_i values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. Asnuciclib down-regulates the RNAPII phosphorylation. Asnuciclib is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion .

HY-137478A

KB-0742 dihydrochloride	CDK	Cancer
KB-0742 dihydrochloride is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity .

HY-137478

KB-0742	CDK	Cancer
KB-0742 is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 has potent anti-tumor activity .

HY-18944

FIT-039	CDK HSV CMV DNA/RNA Synthesis	Infection
FIT-039 is a selective, ATP-competitive and orally active CDK9 inhibitor with an IC₅₀ of 5.8 μM for CKD9/cyclin T1. FIT-039 does not inhibit other CDKs and other kinases. FIT-039 inhibits replication of HSV-1 (IC₅₀ of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a promising antiviral agent for inhibiting drug-resistant HSVs and other DNA viruses.

HY-150562

CDK9-IN-19	CDK	Cancer
CDK9-IN-19 is a highly potent and selective *CDK9* inhibitor with an IC₅₀ value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML) .

HY-151984

CDK9-IN-22	CDK	Cancer
CDK9-IN-22 is a potent *CDK9* inhibitor with IC₅₀s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity .

HY-155245

A09-003	CDK Bcl-2 Family	Cancer
A09-003 is a *CDK-9* inhibitor (IC₅₀: 16 nM). A09-003 inhibits leukemia cell proliferation (IC₅₀: 1.90, 0.86, 2.49, 1.84, 0.48 μM for BDCM, Molm-14, THP-1, U937, MV4-11 cells). A09-003 induces apoptosis and decreases Mcl-1 expression through Thr163 dephosphorylation .

HY-155177

CDK9-IN-27	CDK	Cancer
CDK9-IN-27 (Compound 6a) is a *CDK9* inhibitor (IC₅₀s: 0.424 μM). CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC₅₀s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CDK9-inhibitor

Inhibitors & Agonists